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Abstract
Objectives. To compare the ability of different cyclodextrin polysulphate (CDPS) derivatives to affect
human articular cartilage cell metabolism in vitro.
Methods. OA chondrocytes were cultured in alginate and exposed to 5mg/ml of 2,3,6-tri-O-methyl-b-
cyclodextrin (ME-CD), 2,3-di-O-methyl-6-sulphate-b-cyclodextrin (ME-CD-6-S), 2,6-di-O-methyl-3-
sulphate-b-cyclodextrin (ME-CD-3-S), (2-carboxyethyl)-b-CDPS (CE-CDPS), (2-hydroxypropyl)-b-CDPS
(HP-CDPS), 6-monoamino-6-monodeoxy-b-CDPS (MA-CDPS) or b-CDPS for 5 days. Effects on
IL-1-driven chondrocyte extracellular matrix (ECM) metabolism were assayed by analysis of the accumu-
lation of aggrecan in the interterritorial matrix, IL-6 secretion and qPCR. MA-CDPS, HP-CDPS, CE-CDPS
and CDPS were analysed for their in vitro effect on coagulation and their ability to activate platelets in an
in vitro assay to detect possible cross-reactivity with heparin-induced thrombocytopenia (HIT) antibodies.
Results. The monosulphated cyclodextrins ME-CD-6-S and -3-S failed to affect aggrecan synthesis
and IL-6 secretion by the OA chondrocytes. Polysulphated cyclodextrins MA-CDPS, HP-CDPS,
CE-CDPS and CDPS at 5mg/ml concentrations, on the other hand, significantly induced aggrecan pro-
duction and repressed IL-6 release by the chondrocytes in culture. aPTT and PT for all derivatives were
lengthened for polysaccharide concentrations >50mg/ml. Five micrograms per millilitre of b-CDPS con-
centrations that significantly modulated ECM ground substance production in vitro did not affect aPTT or
PT. Furthermore, CE-CDPS, in contrast to MA-CDPS, HP-CDPS and CDPS, did not significantly activate
platelets, suggesting a minimal potential to induce HIT thromboembolic accidents in vivo.
Conclusions. CE-CDPS is a new, structurally adjusted, sulphated b-cyclodextrin derivative with preserved
chondroprotective capacity and a promising safety profile.
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Introduction
OA is characterized by the degeneration and eventual loss
of cartilage with concurrent changes in the subchondral
bone. While it is generally accepted that mechanical
stress may result in the damage that will set off the OA
process, its progression involves the activities of multiple
auto/paracrine cytokine activities. IL-1 is believed to be a
major regulator of matrix degradation by increasing metal-
loproteinase activity and suppressing the synthesis of
matrix components. In addition to significantly higher
intracellular levels of IL-1b, chondrocytes from fibrillated
cartilage show an up-regulation of the signalling IL-1
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[1]. Despite the attempt of chondrocytes to restore the
homeostasis of their matrix by enhancing insulin-like
growth factor 1 (IGF-1) and TGF-b growth factor activity
[2, 3], the catabolic activity of the OA chondrocyte results
in a continuous net loss of matrix components ensuing
disease progression.
The search for agents that restore the structural defi-
ciencies underlying OA started in the mid-1970s with the
findings that sulphated polysaccharides, e.g. heparin and
chondroitin sulphates, with varying degrees of sulphating,
enhanced the synthesis of extracellular matrix (ECM)
substances by connective tissue cells in culture [4, 5]. In
particular, the polysulphated polysaccharides provided
significant effects on the structure and function of articular
cartilage cells in culture [6, 7]. These effects were also
observed in vivo [810]. Consequently, both xylosan poly-
sulphate and chondroitin polysulphate found their place
in the treatment of osteoarticular pathology in veterinary
and in human medicine, respectively.
Apart from the chondroprotective capacities, however,
these polysulphated polysaccharides were revealed to
possess important biological activities similar to those of
heparin. Such biological activities were clearly shown to
be related to the molecular structure of the polysaccharide
and varied following distinct modifications. In vitro and
in vivo studies on the effects of these polysacchar-
ides on coagulation showed variable effects on thrombin
clotting times. It was, however, the possibility of such
polysulphated polysaccharides to induce heparin-induced
thrombocytopenic thrombosis (HITT) through cross-
reaction with heparin/platelet factor-4 antibodies that
had raised serious concern [11]. These antibodies arise
occasionally when activated thrombocytes release platelet
factor-4 (PF4) during heparin treatment. Heparin then
forms a complex with PF4 that acts as an antigen which
triggers the production of auto-antibodies. These antibo-
dies bind to the complex via their F(ab)0 region and to the
low affinity immunoglobulin gamma Fc region receptor II-b
(FcgRII) [immunoglobulin G (IgG) CD32] of other platelets
via their Fc portion, thereby initiating platelet activation,
aggregation and thromboembolic accidents [12]. It has
been shown that some low-molecular weight heparins as
well as other sulphated polysaccharides, e.g. chondroitin
polysulphates [13], can also bind to heparin-induced
thrombocytopenia (HIT) antibodies in the presence of
PF4 and that their reactivity is dependent on their molecu-
lar weight and the sulphating grade [12, 14, 15].
When, in the 1980s, controversial reports on the occur-
rence of HITT following treatment with chondroitin polysul-
phate came out [13], national and international agencies
for the evaluation of medicinal products insisted that the
previous manufacturer of this polysulphated chondroitin
(Arteparon; Luitpold Werk, Mu ¨nchen, Germany) provided
the conventional drug master files confirming the claims
on efficacy and safety of that drug in human clinics. As
the patent life of chondroitin polysulphate had gone, the
manufacturer at that time did not respond to this demand
and the European formulation of chondroitin polysulphate
was taken off the market in 1994. Neutraceutical industries
then introduced the naturally occurring chondroitin
sulphate to replace chondroitin polysulphate for the use
in degenerative joint disease in humans. In the sole head-
to-head confrontation thus far, the naturally occurring
chondroitin sulphate was inferior to chondroitin polysul-
phate when the chondroprotective effects of both drugs
were assessed in a population with hand OA [16].
Recently, a novel polysulphated polysaccharide, cyclo-
dextrin polysulphate (CDPS) was reported to induce a
down-regulation of intracellular IL-1a and -b and to
cause a concomitant increase in the synthesis of aggre-
can, collagen Type II and fibronectin in the cell-associated
matrix (CAM) of human chondrocytes cultured in alginate
beads [17]. This CDPS also depressed the IL-6 release
of OA chondrocytes by 60% compared with untreated
OA cartilage cells and equalled the levels secreted by
normal cells [17].
CDPS, subcutaneously administered in a rabbit model
of experimental OA, reduced the cartilage lesions and
osteophyte formation in the affected joints [18]. These
data suggest that CDPS positively affects the tissue
pathology underlying OA and this agent can therefore be
classified as a structure or disease-modifying OA drug.
To alleviate possible heparin-related side effects, we
have developed six sulphated b-cyclodextrin derivatives
by introducing hydrophobic substituents on the 2, 3
and/or 6 position, assuming they would preserve their
chondroprotective effect. Next, the effect on coagulation
and the potency to induce thrombocytopenia through
cross-reaction with heparin/PF4 antibodies were assayed.
Once optimized, these derivatives were tested for their
capacity to restore cartilage damage in vitro.
Materials and methods
b-Cyclodextrin derivatives
The 2,3,6-tri-O-methyl-b-cyclodextrin (ME-CD) was pur-
chased from Cyclolab Ltd (Budapest, Hungary) and
served as a non-sulphated control molecule.
b-Cyclodextrins carrying one sulphate on each glucopyr-
anose unit included 2,3-di-O-methyl-6--
sulphate-b-cyclodextrin (ME-CD-6-S: Regis
Technologies Inc.; Morton Grove, IL, USA) and 2,6-di-O-
methyl-3-sulphate-b-cyclodextrin (ME-CD-3-S: Cyclolab
Ltd). Commercially available (2-carboxyethyl)-
b-cyclodextrin (CE-CD containing, on average, three car-
boxyethyl groups: Sigma Chemical Company, St Louis,
MO, USA), (2-hydroxypropyl)-b-cyclodextrin (HP-CD con-
taining seven hydroxypropyl groups: Sigma Chemical
Company) and 6-monodeoxy-6-monoamino-b-cyclo-
dextrin (MA-CD having one OH function replaced by
NH2; Cyclolab Ltd) were used to synthesize the poly-
sulphated b-cyclodextrins or sulphoalkyl-b-cyclodextrins.
Sulphating was achieved according to the proced-
ure described by Astrup et al. [19]. The degree of substi-
tution (DS) of the b-cyclodextrin derivatives was
characterized by elemental analysis of C, N, H and S.
The ratio of sulphur to carbon percentages was used to
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Optimized alkylated cyclodextrin polysulphatesdetermine the DS of the b-cyclodextrin glucopyranose
unit: DS=[%S ma (C) / %C ma (S)] total no. of C,
where ma is the atomic mass (Table 1).
Isolation of articular chondrocytes
Human articular chondrocytes were isolated as described
elsewhere [20]. Briefly, human articular cartilage was
obtained at total knee replacement surgery from femoral
condyles and the tibial plateau of 15 different donors.
None of them had received CSs or cytostatic drugs.
Both visually intact and fibrillated OA cartilage samples
were harvested separately and only OA cartilage was
used for cell culture as OA progression involves the
activities of auto/paracrine IL-1 activity [1] and previous
experiments revealed definite effects of polysulphated
polysaccharides on IL-1-primed chondrocytes after their
isolation from normal cartilage [7]. The cartilage samples
were diced into small fragments and the chondrocytes
were isolated by sequential enzymatic digestion with hya-
luronidase, pronase and collagenase. Isolated cells were
then centrifuged for 10min at 524g, washed three times in
DMEM with 10% (v/v) fetal calf serum (FCS) and counted
with Trypan blue to exclude dead cells. More than 90% of
the cells were viable after isolation. The study was
approved by the Ethical Committee of Ghent University
Hospital. Informed consent was obtained from the
patients.
Cultures in alginate gel
Chondrocytes were cultured in alginate beads to maintain
their differentiated phenotype. The cultures were prepared
as described elsewhere, with some modifications [20, 21].
Chondrocytes suspended in one volume of double-
concentrated Hank’s balanced salts solution (HBSS) with-
out calcium and magnesium (Gibco, Life Technologies,
Paisley, UK) were carefully mixed with an equal volume
of 2% (w/v) autoclaved alginate (low-viscosity alginate
from Macrocystis pyrifera; Sigma) in HBSS. The final cell
concentration was 5 10
6 chondrocytes/ml in 1% algin-
ate. The chondrocyte/alginate suspension was then
slowly dripped through a 23-gauge needle into a
102-mM calcium chloride solution. The beads were
allowed to polymerize for 10min at room temperature.
After removal of the calcium chloride, the beads were
washed three times with 0.15 M sodium chloride.
Alginate beads were cultured in 12-well plates with
1 10
6 cells per culture (each well containing 20 alginate
beads;±50000 chondrocytes per bead) in 3ml DMEM
supplemented with 10% FCS and 50mg ascorbate/ml at
37 C under 5% CO2. Nutrient medium was replaced twice
weekly. It has been shown that ECM metabolism by chon-
drocytes reaches steady state after 1 week in this alginate
culture system [22].
IL-6 release and ECM synthesis by chondrocytes
after treatment with the differently sulphated
b-cyclodextrins in vitro
Cartilage cells obtained from OA cartilage were used
to evaluate the effect of the different b-cyclodextrin poly-
sulphates on the synthesis and accumulation of ECM
aggrecan. Fifteen donor samples allowed seven polysac-
charides to be compared 611 times with the control situ-
ation. At Day 5 of culture, the OA chondrocytes of each
donor were exposed to 5mg/ml of, respectively, ME-CD,
ME-CD-3-S, ME-CD-6-S, 6-monoamino-6-monodeoxy-
b-CDPS (MA-CDPS), (2-hydroxypropyl)-b-CDPS (HP-
CDPS), (2-carboxyethyl)-b-CDPS (CE-CDPS) and CDPS.
After 5 additional culture days, media were collected and
stored at  20 C. The cells were separated from their al-
ginate coat by dissolving the alginate with 3ml of 55-mM
tri-sodium citrate dehydrate pH 6.8, 0.15 M NaCl at 25 C
for 10min. The resulting suspension was centrifuged at
524g for 10min to separate the supernatant containing
the constituents of interterritorial matrix (IM) from the
cells with their CAM. The aggrecan content (Biosource,
Merelbeke, Belgium) and IL-6 (R&D Systems, Abingdon,
UK) release in the IM was assayed by ELISA according to
the manufacturer’s instructions. All experiments were
performed in triplicate. Chondrocytes from four additional
patients [mean (S.D.) 63.5 (9.3) years] were isolated and
cultured as described above. After the culture period,
Trizol (Invitrogen, Life Technologies, Paisley, UK) was
added to the isolated cells. RNA was extracted and
cDNA prepared as previously described [23]. Real-time
PCR was performed using the ABI 7000 Sequence
Detection System (Applied Biosystems, Carlsbad, CA,
TABLE 1 Chemical analysis of the different b-cyclodextrins
b-Cyclodextrin
Elemental analysis
S-substitution DS/glucopyranose C, % H, % N, % S, %
ME-CD 0.00
a
Heptakis ME-CD-3-S 1.00
a
Heptakis ME-CD-6-S 28.66 4.50 <0.05 9.77 7.12 1.02
Sulphated MA-CDPS 16.11 2.78 0.47 16.34 15.96 2.28
Sulphated CE-CDPS 16.80 2.63 <0.05 15.33 17.34 2.47
Sulphated HP-CDPS 18.91 3.28 <0.05 16.40 20.48 2.92
CDPS 17.28 2.86 <0.05 16.94 15.41 2.21
aManufacturer’s data. S-substitution: number of sulphate groups per b-cyclodextrin; DS/glucopyranose:
sulphate groups per b-cyclodextrin glucopyranose unit.
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20ml of iTaq Sybr Green Supermix with Rox (Bio-Rad,
Hercules, CA, USA), primers (Invitrogen) and water and
was performed in triplicate. The following primer se-
quences were used: aggrecan Fw: TGGTGAAAGGCATC-
GTGTTC, aggrecan Rev: GTGGCAATGATGGCACTGTT;
Col2A1 Fw: GGCAATAGCAGGTTCACGTACA, COL2A1
Rev: CGATAACAGTCTTGCCCCACTT; BMP-2 Fw: CCA-
ACACTGTGCGCAGCTT, BMP-2 Rev: AAGAATCTCCGG-
GTTGTTTTCC; TIMP1 Fw: TGACATCCGGTTCGTCTACA,
TIMP1 Rev: TGCAGTTTTCCAGCAATGAG; Col1A1 Fw:
TGCCATCAAAGTCTTCTGCAA, COL1A1 Rev: CGCCAT-
ACTCGAACTGGAATC; SOX-9 Fw: GCTCAGCAAGACG-
CTGGGCA, SOX-9 Rev: ATGTGCGTCTGCTCCGTGGC;
MMP2 Fw: CTACGATGGAGGCGCTAATG, MMP2 Rev:
GGCAGCCATAGAAGGTGTTC; ADAMTS5: TaqMan
Gene expression Assay (ABI). All primer sequences were
validated by melting curve analysis and efficiency ana-
lysis. qPCR and data analysis were performed as
described earlier [23, 24].
b-Cyclodextrins and blood coagulation activities
MA-CDPS, HP-CDPS, CE-CDPS and CDPS were pre-
pared as buffered solutions at various concentrations.
The polysaccharides were incubated with normal pooled
plasma, prepared out of 40 healthy volunteers and ana-
lysed for their effects on aPTT, PT and fibrinogen levels on
an STA Compact (Diagnostica Stago, Asnie `res, France)
coagulation analyser according to the manufacturer’s
instructions.
b-Cyclodextrins and HIT
The activation of healthy donor thrombocytes by HIT pa-
tient anti-heparin/PF4 antibodies in the presence of hep-
arin and the differently sulphated forms of b-cyclodextrin
was tested. Plasma of patients that experienced HIT
thromboembolic accidents following the administration
of heparin and which showed anti-heparin/PF4 antibodies
(HIT Abs) on immunological and flow cytometric tests
[2527] were selected for these assays. The expression
of CD62p by the activated platelets was assayed by
means of flow cytometry with a FC500 Beckman Coulter
(Beckman Coulter, Analis, Belgium).
Platelet-rich plasma (PRP) solution was prepared
by slow centrifugation (10min at 180 g) of fresh citrate
anti-coagulated blood (1 : 9 v/v, 0.129mol/l or 3.8%
tri-sodium citrate buffer), obtained from normal donors.
HIT Ab-positive plasma samples from patients and HIT
Ab-negative control plasma from healthy donors were
prepared by double centrifugation (15min at 1157g)o f
fresh citrate anti-coagulated blood. Seventy microlitres
of PRP was incubated with 20ml of HIT Ab containing
plasma in the presence of different concentrations of
heparin (0 and 0.3IU/ml) or the different b-cyclodextrins
(0 and 5mg/ml). Experiments with each HIT Ab-positive
plasma sample were repeated independently using
thrombocytes of two donors (A and B), to avoid the
possibility of non-reactive platelets.
Following the initial 40-min incubation step, 5ml of the
platelet solution were transferred to a fresh tube with 85ml
PBS containing 1% BSA and 0.1% sodium azide, 5ml
(0.25mg) monoclonal anti-CD41 Abs [phycoerythrin (PE)-
Texas Red energy coupled dye (ECD)-conjugated,
Beckman Coulter] and 5ml (0.125mg) of anti-CD62p Ab
(PE-conjugated, Beckman Coulter). CD41 (glycoprotein
IIb) is a selective marker of platelets and platelet precur-
sors. CD62p is a constituent of a-granules and is released
to the platelet surface on activation [12, 14].
After 20min of incubation at room temperature, the
total volume of the platelet suspension was adjusted to
600ml buffered solution and evaluated without delay by
flow cytometry. Twenty thousand events per sample
were analysed and the platelet populations were gated
by side scatter characteristics and the platelet marker
CD41. Activated platelets (CD62p
+) were distinguished
from resting platelets by the CD62p-PE expression
(Fig. 1). The fraction of activated platelets among the
total platelet population was determined and relative
CD62p ratios to the internal controls were calculated.
[ratio: %CD62p
+ (0.3IU heparin or 5mg/ml b-cyclodextrin
derivate)/%CD62p
+ (0IU heparin or 0mg/ml b-cyclodextrin
derivate)]. Test results for the heparin-treated platelets
were evaluated by a scoring system adapted from Jy
et al. [14]. Control tests were scored positive when the
calculated ratios of at least two donors were >2, which
is based on previously obtained results with normal
individuals.
To evaluate the potential of different b-cyclodextrins to
induce platelet activation, both the percentages and ratios
of CD62p
+ platelets after incubation with the respective
b-cyclodextrin were statistically compared with the per-
centage and the ratio of CD62p
+ platelets after heparin
incubation. The number of normal individuals who were
tested with the b-cyclodextrin derivates was too small to
set a correct cut-off for these ratios.
Statistical analysis
To study the impact of the changes in the chondrocyte
cultures after CDPS treatment, mean IL-6 and aggrecan
concentrations were calculated from triplicate chondro-
cyte cultures of each donor. Student’s t-tests were used
to test significance of differences between untreated
controls and cultures after exposure to different CDPSs.
Cross-reactivity with heparin of the polysaccharides on
in vitro-induced platelet activation was analysed by
Wilcoxon signed-rank test.
Results
Chemical analysis of the different b-cyclodextrins
From the data provided by the elemental analysis of the
different b-cyclodextrin preparations (Table 1), ME-CD-
6-S, as ME-CD-3-S, appeared to contain one sulphate
group per glycopyranose unit. Sulphating occurred at
positions 6 and 3 of each glucopyranose unit in ME-CD-
6-S and ME-CD-3-S, respectively. HP-CDPS showed
2.92 sulphate groups per glucopyranose. Therefore, two
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of the hydroxypropyl group, have been substituted by sul-
phate. Equally, CE-CDPS with glucopyranoses containing
2.47 sulphate groups had all remaining glucopyranose
OH-functions substituted by sulphate. Although the sul-
phating procedure should have resulted in 3-sulphated
glucopyranoses, degrees of sulphating of 2.28 and 2.21
of each glucopyranose were calculated for MA-CDPS and
CDPS, respectively. To conclude, the in vitro tests were
done with one unsulphated cyclodextrin: ME-CD, two
monosulphated cyclodextrins sulphated on different C
atoms: ME-CD-3-S and -6-S and 4 CDPSs with degrees
of sulphating ranging from 2 to 3: CDPS, MA-, CE- and
HP-CDPS. Chemical structures of the different CDPS are
given in Fig. 2.
Effects on ECM production and inhibition of IL-6
release by differently sulphated b-cyclodextrins
The unsulphated ME-CD failed to promote aggrecan
synthesis or to affect IL-6 release and was used as a
control in the experiments on isolated chondrocytes.
Furthermore, the monosulphated cyclodextrins ME-CD-
3-S and -6-S also failed to affect chondrocyte aggrecan
synthesis and IL-6 secretion. The bisulphated (CDPS,
MA-CDPS) and trisulphated b-cyclodextrins (HP-CDPS,
CE-CDPS), however, significantly enhanced chondro-
cyte aggrecan synthesis. When compared with the con-
trols, average percentage increases of 51.6 (P=0.009),
41.0% (P=0.006), 30.4% (P=0.020) and 67.3%
(P=0.007) for CDPS, MA-CDPS, HP-CDPS and
CE-CDPS, respectively, were noted (Fig. 3A). These
highly sulphated b-cyclodextrins significantly repressed
chondrocyte IL-6 secretion by  25% with P<0.001 for
the four polysaccharides tested (Fig. 3B). Based on the
results of the blood coagulation and HIT-analysis, CE-
CDPS was selected for further analysis on chondrocyte
metabolism. qPCR analyses were performed of additional
ECM genes (COL2A1, aggrecan, COL1A1), catabolic en-
zymes and enzyme inhibitors (ADAMTS5, MMP2, TIMP-1),
transcription factors (SOX-9) and growth factors (Bone
Morphogenetic Protein 2) to provide further insights into
the effect of CE-CDPS on chondrocyte metabolism. In par-
allel, with the ELISA analysis mentioned above, aggrecan
gene expression was elevated in three of four patients ana-
lysed. No effects were observed on collagen expression
(COL2A1 and COL1A1). The MMP-2 enzyme showed a
lower expression upon stimulation with CE-CDPS in three
patients (in one of the patients no expression of MMP2
could be detected). Upon CE-CDPS stimulation, a signifi-
cant elevated expression was observed for the transcrip-
tion factor SOX-9 (on average 3.2-fold induction),
confirming the positive effect of CE-CDPS on the chondro-
cyte’s anabolic activity (Fig. 3CE).
b-Cyclodextrin effects on blood coagulation activities
With increasing concentrations, the aPTT values stag-
nated up to a concentration of 5mg/ml for all the CDPS
derivatives studied. Above 50mg/ml no clot formed for the
FIG.1In vitro activation of platelets by HIT ab-positive plasma with heparin. Percentages of cell staining with CD62p
after addition of 5ml heparin (A1 and A2: 100IU/ml; B1 and B2: 0.3IU/ml; C1 and C2: 0IU/ml) in the absence (A1, B1 and
C1) or presence (A2, B2 and C2) of HIT ab-positive plasma. Platelets gated on side scatter (SS log) and CD41 activity (D).
The interface channel for positivity was set at the point where <2% of the control fluorescence was positive.
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Sara Groeneboer et al.FIG.3(A) Percentage changes in aggrecan production by OA chondrocytes treated with b-CDPS derivatives.
Dots represent mean values of triplicate cultures of one patient. Lines represent the overall mean. (B) Percentage
changes in IL-6 release by OA chondrocytes treated with b-CDPS derivatives. Dots represent mean values of triplicate
cultures of one patient. Lines represent the overall mean. (CE) Relative expression of aggrecan, MMP2 and SOX-9,
respectively, as determined by qPCR. Four additional patient samples were stimulated with CE-CDPS and compared
with controls. Dots represent the mean expression of duplicate cultures. No expression of MMP2 was observed in one of
the samples.
FIG.2Chemical structures of b-cyclodextrin derivatives.
ME-CD
ME-CD-3S
ME-CD-6S
MA-CDPS
CE-CDPS
HP-CDPS
CDPS
R= [-CH3]21
R= [-CH3]14
R= [-CH3]14
R= [-NH2]1
R= [-CH2CH2COOH]3
R= [-CH2CHOSO3CH3]7
R= [-SO3]15
or
or
or
or
or
or
[-SO3]14
H6
[-SO3]18
[-SO3]16
[-SO3] 7
[-SO3] 7
or H6
www.rheumatology.oxfordjournals.org 1231
Optimized alkylated cyclodextrin polysulphatesderivatives studied in the observation time of the experi-
ment (Fig. 4A). The same tendency was observed for
PT values, except for the far more limited increase in PT
for concentrations >50mg/ml (Fig. 4B). Minor decreases
were observed in fibrinogen concentrations (mg/ml) after
incubation with 50 or 100mg/ml of MA-CDPS, HP-CDPS,
CE-CDPS or CDPS, respectively (Fig. 4C). No influence
on the blood coagulation cascade could thus be detected
at concentrations that highlighted a chondroprotective
effect in vitro.
Induction of platelet activation
All HIT Ab-positive plasma samples showed platelet
heparin activation ratios %CD62p
+ (0.3IU heparin)/%
CD62p
+ (0 I U heparin) >2 for the two donors, indicating
an activation of platelets by heparin/PF4 antibodies.
Platelets were not activated by heparin or any of the
b-CDPS derivatives in the absence of patient’s HIT Ab
(data not shown).
Immunological cross-reactivity between heparin and
some of the polysulphated b-cyclodextrins became evi-
dent as HP-CDPS, MA-CDPS and CDPS induced platelet
activation in the presence of the plasma samples of
the individuals that had developed HIT Ab upon previous
exposure to heparin (Fig. 1). Paired analysis of both ratios
and percentages of CD62p
+ cells confirmed a significant
difference (P=0.017 for percentages and P=0.012
for ratios) between heparin and CE-CDPS-incubated
platelets, indicating that CE-CDPS exhibited no cross-
reactivity with the heparin/PF4 antibodies (Table 2).
Moreover, the P-values calculated from the paired
analysis of ratios and percentages of activated plate-
lets between CE-CDPS and each of the other analysed
cyclodextrins was <0.05.
Discussion
Among the polysulphated polysaccharides shown to im-
prove connective tissue cell ECM metabolism in vitro and
in vivo [410], chondroitin polysulphate was mainly found
to be applicable in the treatment of osteoarticular path-
ology. The safety of this drug in human clinics, however,
became controversial. The purpose of this study was,
therefore, to search for more advanced polysaccharide
polysulphates with a preserved chondroprotective cap-
acity, a reduced effect on coagulation and, imperatively,
a reduced risk for HIT.
The structure-modifying capacities of CDPS have been
evidenced previously. In vitro, all three a-, b- and g-CDPS
equally and significantly improved the synthesis and
accumulation by chondrocytes of CAM macromolecules
e.g. aggrecan, Type II collagen and fibronectin [17]. It was
shown that this enhanced repair function resulted from a
down-modulation of the autocrine catabolic IL-1 pathway:
b-CDPS inhibited the synthesis of IL-6 in both normal
and OA chondrocytes. Although the experiments were
not performed in the presence of IL-1-blocking antibodies,
it is supposed that b-cyclodextrin affected the IL-1 loop
and did not directly impede the production of IL-6 [17].
While in osteoarthritic chondrocytes both autocrine
anabolic (IGF-1) and catabolic (IL-1) pathways are
up-regulated, the selective inhibition of IL-1 resulted in
a dramatic improvement of the repair function. In vivo,
this repair-promoting effect was obvious when rabbits,
in which the anterior cruciate ligament of the knees were
sectioned, failed to develop cartilage degradation when
treated with s.c. injections of 1mg/kg g-CDPS once
weekly [18]. In these in vivo experiments, however, a
15-times higher dose (5mg/kg s.c. three times weekly)
caused haemorrhages in some of the treated animals
and a 90-times higher dose (30mg/kg s.c. three times
weekly) even caused fatal haemorrhages in most animals
[18]. A series of polysulphated cyclodextrin derivatives
were thus synthesized to come across potentially less
harmful treatments. b-Cyclodextrins with different alkyl
substitutions on distinct  OH groups allowed for the
FIG.4Effects of the b-CDPS derivatives on variables of
plasma coagulation activity in a pool of 40 serum samples.
The assays were done once as the results of these types
of tests are particularly consistent. (A) aPTT, in s; (B) PT,
in s; and (C) fibrinogen, in mg/ml; abscissa: sulphated
cyclodextrins, in mg/ml.
100.0 50.0 10.0 5.0 2.0 1.0 0.5
0
50
100
150
200
0.0
CDPS
MA-CDPS
CE-CDPS
HP-CDPS
Control
A aPTT, s
100.0 50.0 10.0 5.0 2.0 1.0 0.5 0.0
0
5
10
15
20
25 B PT, s
0
100.0 50.0 10.0 5.0 2.0 1.0 0.5 0.0
C Fibrinogen, mg/ml
1.0
2.0
3.0
4.0
5.0
Sulphated cyclodextrin, µg/ml
1232 www.rheumatology.oxfordjournals.org
Sara Groeneboer et al.synthesis of differently sulphated b-cyclodextrins with dif-
ferent biological activities and toxicological profiles. The
introduction of distinct alkyl groups on the b-cyclodextrin
glucopyranose unit, for example, did not prolong the aPTT
in vitro, suggesting a reduced anti-coagulant activity com-
pared with CDPS [28, 29]. These compounds were tested
on their potential to improve chondrocyte repair function,
on their anti-coagulant properties and on their potential to
activate human platelets in an in vitro model of HITT.
Both ME-CD-3-S and ME-CD-6-S were unable to affect
IL-6 release and aggrecan production by chondrocytes
in vitro, indicating that monosulphated b-cyclodextrin
derivatives were unable to affect cartilage metabolism.
The presence of at least two sulphate groups per gluco-
pyranose unit of the b-cyclodextrin ring—irrespective
of their position or spacing—was necessary to block
down-stream IL-1 events and to warrant an enhance-
ment of the chondrocyte’s anabolic function. It was con-
cluded that the introduction of alkyl groups was of minor
importance compared with the degree of sulphating,
when cartilage protection was considered. Additional ex-
periments confirmed the positive effect of CE-CDPS,
mainly, on the chondrocyte’s anabolic activity (SOX-9,
aggrecan). On the catabolic side, MMP2 expression
was slightly decreased upon CE-CDPS stimulation. To
provide in-depth insights on the potential anti-catabolic
activity of CE-CDPS, future experiments on cell cultures
co-stimulated with pro-inflammatory cytokines are
warranted.
The in vitro tests with MA-CDPS, HP-CDPS, CE-CDPS
and CDPS on blood coagulation revealed dose-related
anti-coagulant effects but no remarkable mutual
difference between the derivatives. At presumed thera-
peutic concentrations (5mg/ml in vitro), none of the poly-
sulphated b-cyclodextrin derivatives revealed an inhibition
of the blood coagulation cascade. Moreover, MA-CDPS,
HP-CDPS and CDPS showed an interaction with the
heparin/PF4 antibodies, triggering activation of the plate-
lets. Introduction of an average of three carboxyethyl
chains on the b-cyclodextrin ring, in contrast, significantly
decreased platelet activation in comparison with heparin
and the other b-CDPS derivatives (P<0.05) in this
in vitro model of HIT, indicating that CE-CDPS exhibits
no cross-reactivity with the heparin/PF4 antibodies.
In vitro testing of the interaction of CDPS derivatives
with HIT Ab-positive sera in some way constrain the
conclusions of the present study. There are no data avail-
able on the ability of the derivatives to induce auto-
immune antibodies in vivo themselves. A previously
published case report on the induction of HITT after chon-
droitin polysulphate therapy showed antibodies directed
against epitopes of chondroitin polysulphate, but HITT
only developed after an additional heparin treatment,
which suggests cross-reactivity [13]. These data suggest
the potential of polysulphated polysaccharides to induce
auto-antibodies although these polysaccharides do not
invariably induce HITT themselves. Nevertheless, being
low-molecular weight polysaccharides, the possible
occurrence of HITT following the administration of CDPS
in vivo may be less probable as classical HITT rarely
occurred with low-molecular weight forms of heparin.
In summary, these studies aimed at revealing more
advanced polysaccharide polysulphates with chondro-
protective capacities. We showed that poly- but not
TABLE 2 Platelet activation by heparin and polysulphated b-cyclodextrin derivatives
Treatment
Patient 1 Patient 2 Patient 3 Patient 4
P-values
dA dB dA dB dA dB dA dB Heparin MA-CDPS CE-CDPS HP-CDPS
Heparin
CD62p
+ % 45.5 14.3 45.6 15.1 60.3 42.3 34.8 56.4 Reference
Ratio 4.2 2.2 2.8 3.9 4.3 8.2 2.7 2.8 Reference
MA-CDPS
CD62p
+ % 74.8 69.9 9.6 17.4 16.7 32.6 51.1 63.6 0.779 Reference
Ratio 5.2 5.5 1.4 3.5 1.9 8.2 3.5 3.1 0.779 Reference
CE-CDPS
CD62p
+ % 13.9 14.4 2.4 1.1 7.9 10.2 22.9 45.0 0.017 0.012 Reference
Ratio 1.8 2.2 1.1 1.2 1.4 2.7 2.2 2.4 0.012 0.012 Reference
HP-CDPS
CD62p
+ % 67.6 53.0 0.1 1.2 23.3 17.1 63.2 60.7 0.779 0.123 0.025 Reference
Ratio 4.9 5.1 1 1.1 2.1 4.7 4.6 2.8 0.484 0.123 0.036 Reference
CDPS
CD62p
+ % 76.1 73.1 27.5  2.8 42.7 34.1 63.5 58.1 0.484 0.327 0.017 0.093
Ratio 5.8 6.5  0.7 2.5 7 4.4 2.5 0.889 0.889 0.025 0.123
Platelets from two different donors (dA and dB) were incubated with plasma samples containing HIT ab from four patients
(Patients 1, 2, 3 and 4) and with the different sulphated polysaccharides. CD62p
+ %: percentage increases in CD62p
+
platelets; ratio: %CD62p
+ (0.3IU heparin or 5mg/ml sulphated polysaccharide)/ %CD62p
+ (0IU heparin or 0mg/ml sulphated
polysaccharide).
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potential of OA chondrocytes in vitro. From these poly-
sulphated b-cyclodextrin derivatives, CE-CDPS had a
better safety profile when the in vitro induction of HIT
was considered. Additional pre-clinical studies in models
of OA are underway to evaluate the in vivo chondropro-
tective efficacy of CE-CDPS.
Rheumatology key messages
. CDPSs restore synthesis of ECM molecules of OA
chondrocytes, depending on the sulphation degree.
. Carboxyethyl-b CDPS can restore OA chondrocyte
metabolism without enhanced risk of HIT.
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